Develops potential medicines for adults with generalized anxiety disorder, major depressive disorder and autism spectrum disorder.
10-K for FY2025, filed Feb 26, 2026
No revenue reported yet.
10-K for FY2025, filed Feb 26, 2026
10-Q for Q3 FY2026, filed Nov 9, 2026
−$51MView ↗
Treatment scope
The older report described development for generalized anxiety disorder and attention deficit hyperactivity disorder; the latest report describes development for generalized anxiety disorder and major depressive disorder.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Feb 26, 2026Our lead product candidate, MM-120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that we are developing for…View ↗
Our first lead product candidate, DT120 ODT, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that we are…View ↗
Competes with AtaiBeckley, Compass, GH Research, Helus, Otsuka, Johnson & Johnson, Intra-Cellular, Axsome, Resilient, Nova Mentis Life Science, Mycrodose Therapeutics, Novartis, Roche, Pfizer, Biogen, Jazz Pharmaceuticals, Supernus Pharmaceuticals, AbbVie, Neumora Therapeutics, and Praxis Precision Medicines
10-K for FY2025, filed Feb 26, 2026Our most advanced product candidate, DT120 ODT, is in Phase 3 development for GAD and MDD, with additional psychiatric indications under…View ↗
Loading...